Skinetiq is a Vietnamese direct-to-consumer company that owns digital-first science-backed skin care brand, Candid
Marico has said that its wholly owned subsidiary, Marico South-East Asia Corporation (MSEA), has entered into definitive agreements to acquire a 75 per cent equity stake in Skinetiq Joint Stock Company, for aggregate consideration of upto Vietnamese Dong (VND) 750 Billion (Rs 261.6 crore, based on conversion rate as on 06 February 2026.
Skinetiq is a Vietnamese direct-to-consumer company that owns digital-first science-backed skin care brand, Candid. Skinetiq also holds exclusive distribution rights in Vietnam for the globally renowned luxury clinical skincare brand, Murad.
“The investment in Skinetiq reflects our commitment to building a strong premium beauty play in Vietnam and advancing our D2C strategy internationally. Vietnam remains a priority market for us, driven by its strong macroeconomic fundamentals and rapidly evolving beauty landscape. Skinetiq’s digital-led model and science-backed portfolio align seamlessly with Marico’s vision for the future of beauty and portfolio premiumisation,” stated Saugata Gupta, Managing Director and Chief Executive Officer, Marico.
The transaction aligns with Marico’s long term strategy of building a strong premium beauty play in Vietnam, while enabling participation in the country’s growing D2C beauty market and also realizing various operational synergies. The transaction is expected to be completed within 90 days from the date of signing definitive agreements, subject to receipt of requisite regulatory approvals and customary closing conditions.
“Partnering with Marico gives us the platform, expertise and resources to build a strong foundation for long term, sustainable growth. I’m excited to embark on our next phase with a company that shares our ambition and commitment to excellence, as we scale our innovation pipeline and deepen our connection with Vietnamese consumers,” highlighted Bui Ngoc Anh, Founder and Executive Chairman, Skinetiq JSC.
The company added that MSEA has the right to acquire the remaining shares of Skinetiq after completion of FY28 at a consideration to be determined at such time, subject to achievement of certain milestones, requisite approvals and terms and conditions under the definitive agreements.
